Antithrombin Cambridge, 384 Ala to Pro: A new variant identified using the polymerase chain reaction
- 28 August 1989
- journal article
- case report
- Published by Wiley in FEBS Letters
- Vol. 254 (1-2) , 174-176
- https://doi.org/10.1016/0014-5793(89)81033-6
Abstract
An antithrombin III variant was identified in the plasma of a female patient with a history of recurrent thromboses. The variant was shown to have normal antigenic levels but reduced heparin and progressive inhibitory activity consistent with an abnormality affecting function at the reactive centre. Polymerase chain reaction amplification of exon 6 of the gene with direct sequencing showed a point mutation resulting in the substitution of a proline for alanine at position 384. This substitution will predictably alter the conformation of the peptide loop containing the reactive centre of the molecule.Keywords
This publication has 8 references indexed in Scilit:
- Diagnosis of α1antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction productsNucleic Acids Research, 1988
- Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to HisBlood, 1987
- Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell AnemiaScience, 1985
- Human α1-proteinase inhibitorJournal of Molecular Biology, 1984
- Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH)Thrombosis Research, 1977
- Investigations on Antithrombin III in Normal Plasma and SerumBritish Journal of Haematology, 1975
- Anticoagulant Action of HeparinNature, 1973
- The Purification and Mechanism of Action of Human Antithrombin-Heparin CofactorJournal of Biological Chemistry, 1973